BioGaia AB, commonly referred to as BioGaia, is a leading biotechnology company headquartered in Sweden. Founded in 1990, the company has established itself as a pioneer in the development of probiotic products, focusing on gut health and overall well-being. With a strong presence in Europe, North America, and Asia, BioGaia operates within the health and wellness industry, specifically in the probiotics sector. The company’s core offerings include a range of probiotic supplements and functional foods, distinguished by their unique strains of Lactobacillus reuteri. BioGaia's commitment to scientific research and innovation has led to numerous key milestones, including partnerships with major global brands and a robust portfolio of clinical studies supporting their products. Recognised for its market leadership, BioGaia continues to enhance its reputation through ongoing advancements in probiotic technology and consumer education.
How does Biogaia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Biogaia's score of 59 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, BioGaia AB, headquartered in Sweden, reported total greenhouse gas emissions of approximately 7,300,000 kg CO2e across all scopes. This includes about 73,000 kg CO2e from Scope 1 emissions, primarily from mobile combustion, and about 33,000 kg CO2e from Scope 2 emissions, calculated on a market-based approach. The company also reported significant Scope 3 emissions, totalling approximately 7,168,000 kg CO2e. In 2023, BioGaia's emissions were slightly lower, with total emissions of about 6,284,000 kg CO2e, comprising approximately 77,000 kg CO2e from Scope 1 and about 32,000 kg CO2e from Scope 2. The Scope 3 emissions for that year were around 6,284,000 kg CO2e. BioGaia has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions by 46% by 2030, using 2019 levels as a baseline. This target has been approved by the Science Based Targets initiative (SBTi) and is aligned with the goal of limiting global warming to 1.5°C. The company is also committed to measuring and reducing its Scope 3 emissions, although specific targets for these emissions have not been detailed. Looking ahead, BioGaia has long-term goals to reduce its Scope 1 and Scope 2 emissions to near zero by 2050. These commitments reflect the company's proactive approach to addressing climate change and its dedication to sustainability within the pharmaceuticals, biotechnology, and life sciences sector.
Access structured emissions data, company-specific emission factors, and source documents
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|
Scope 1 | 7,000 | 00,000 | - | 00,000 | 00,000 | 00,000 | 00,000 |
Scope 2 | 61,000 | 00,000 | 00,000 | 0,000 | 00,000 | 00,000 | 00,000 |
Scope 3 | 2,438,000 | 0,000,000 | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biogaia is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.